Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Arbutus Biopharma Corp (NASDAQ: ABUS) was $3.34 for the day, up 3.73% from the previous closing price of $3.22. In other words, the price has increased by $3.73 from its previous closing price. On the day, 0.88 million shares were traded. ABUS stock price reached its highest trading level at $3.355 during the session, while it also had its lowest trading level at $3.17.
Ratios:
Our analysis of ABUS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.02 and its Current Ratio is at 7.02. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 14 ’24 when MANCHESTER KEITH S sold 8,846 shares for $3.69 per share. The transaction valued at 32,637 led to the insider holds 46,069 shares of the business.
Sims Karen sold 4,358 shares of ABUS for $10,078 on Feb 02 ’24. The Chief Medical Officer now owns 125,542 shares after completing the transaction at $2.31 per share. On Feb 02 ’24, another insider, HASTINGS DAVID C, who serves as the Chief Financial Officer of the company, sold 9,593 shares for $2.31 each. As a result, the insider received 22,184 and left with 181,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 632903232 and an Enterprise Value of 511869216. For the stock, the TTM Price-to-Sale (P/S) ratio is 93.90 while its Price-to-Book (P/B) ratio in mrq is 5.92. Its current Enterprise Value per Revenue stands at 75.922 whereas that against EBITDA is -6.636.
Stock Price History:
The Beta on a monthly basis for ABUS is 1.76, which has changed by 0.35294116 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, ABUS has reached a high of $4.72, while it has fallen to a 52-week low of $2.27. The 50-Day Moving Average of the stock is -2.42%, while the 200-Day Moving Average is calculated to be -4.82%.
Shares Statistics:
ABUS traded an average of 835.44K shares per day over the past three months and 806970 shares per day over the past ten days. A total of 189.44M shares are outstanding, with a floating share count of 147.38M. Insiders hold about 22.22% of the company’s shares, while institutions hold 53.52% stake in the company. Shares short for ABUS as of 1735603200 were 5948529 with a Short Ratio of 7.12, compared to 1732838400 on 5821160. Therefore, it implies a Short% of Shares Outstanding of 5948529 and a Short% of Float of 3.9800000000000004.
